ORLANDO-“Nonsteroidal anti-inflammatory drugs (NSAIDs) confer protection against the common GI cancers, not only against colon and rectal cancer, which we’ve known about, but also in the esophagus and stomach, where the protection was at least as strong,” Michael Langman, MD, said at the Digestive Disease Week meeting.
ORLANDONonsteroidal anti-inflammatory drugs (NSAIDs) confer protection against the common GI cancers, not only against colon and rectal cancer, which weve known about, but also in the esophagus and stomach, where the protection was at least as strong, Michael Langman, MD, said at the Digestive Disease Week meeting.
Dr. Langman led a research team at the University of Birmingham in England in a large Medical Research Council case-control study based on the Birmingham groups General Practitioner Research Database (GPRD). This vast resource contains data on all prescriptions written by general practitioners for 3.6 million people in the United Kingdom. It also contains information on diagnostic outcomes, and it extends back 36 months.
Our hypothesis was that if NSAIDs protect against cancer, we would see less of the disease in people who had many prescriptions for NSAIDs, Dr. Langman said.
The group examined NSAID prescription rates for cancer patients 13 to 36 months before their diagnosis. The cancers included five gastrointestinal cancers (esophagus, stomach, pancreas, colon, and rectum) and four others (bladder, breast, lung, and prostate). There were 1,156 cancer cases, each matched for age and sex with three controls.
Trends analysis indicated NSAID protection against all gut epithelial tumors but did not provide evidence of benefit against all cancers.
The findings on the colon and rectum were not new. We had only had suggestive data regarding the esophagus and stomach until now, though, Dr. Langman said. This study provides good evidence that the protection against cancers of the esophagus and stomach is at least as strong as that conferred in the colon and rectum.
There was no protection shown against either bladder or breast cancers. With lung cancer, there was the suggestion of a trend but nothing significant, Dr. Langman said, and the findings on prostate cancer were similarly insignificant.
Dr. Langman speculated on possible reasons for the protection working within the gut but not outside it. It may be straightforward that the NSAID concentration is strongest in the gut and less elsewhere. Outside the digestive tract, the drugs may be diluted and thus offer less protection. Or it may be that the other organ systems are resistant to the protection.